Abstract

BackgroundDeciding which health technologies to fund involves confronting some of the most difficult choices in medicine. As for other countries, the Israeli health system is faced each year with having to make these difficult decisions. The Public National Advisory Committee, known as ‘the Basket Committee’, selects new technologies for the basic list of health care that all Israelis are entitled to access, known as the ‘health basket’. We introduce a framework for health technology prioritization based explicitly on value for money that enables the main variables considered by decision-makers to be explicitly included. Although the framework’s exposition is in terms of the Basket Committee selecting new technologies for Israel’s health basket, we believe that the framework would also work well for other countries.MethodsOur proposed prioritization framework involves comparing four main variables for each technology: 1. Incremental benefits, including ‘equity benefits’, to Israel’s population; 2. Incremental total cost to Israel’s health system; 3. Quality of evidence; and 4. Any additional ‘X-factors’ not elsewhere included, such as strategic or legal factors, etc. Applying methodology from multi-criteria decision analysis, the multiple dimensions comprising the first variable are aggregated via a points system.ResultsThe four variables are combined for each technology and compared across the technologies in the ‘Value for Money (VfM) Chart’. The VfM Chart can be used to identify technologies that are good value for money, and, given a budget constraint, to select technologies that should be funded. This is demonstrated using 18 illustrative technologies.ConclusionsThe VfM Chart is an intuitively appealing decision-support tool for helping decision-makers to focus on the inherent tradeoffs involved in health technology prioritization. Such deliberations can be performed in a systematic and transparent fashion that can also be easily communicated to stakeholders, including the general public. Possible future research includes pilot-testing the VfM Chart using real-world data. Ideally, this would involve working with the Basket Committee. Likewise, the framework could be tested and applied by health technology prioritization agencies in other countries.

Highlights

  • Deciding which health technologies to fund involves confronting some of the most difficult choices in medicine

  • The Value for Money (VfM) Chart is capable of representing potentially any number of technologies, for simplicity and so that the chart can be read on a journal page, we have restricted ourselves to 18 illustrative technologies

  • It should be recognized that the 18 technologies are presented solely for illustrative purposes and should not be regarded as the same as actual technologies discussed by the Basket Committee; and it is not appropriate nor feasible to compare the Committee’s decisions with the illustrative ones presented here

Read more

Summary

Introduction

Deciding which health technologies to fund involves confronting some of the most difficult choices in medicine. As for other countries, the Israeli health system is faced each year with having to make these difficult decisions. The Public National Advisory Committee, known as ‘the Basket Committee’, selects new technologies for the basic list of health care that all Israelis are entitled to access, known as the ‘health basket’. Deciding which technologies to fund (and which not to) involves confronting some of the most difficult choices in medicine. As for other countries, the Israeli health system, which is committed to an explicit prioritization process for new technologies, is faced each year with having to make these difficult decisions. In 2010 the Committee had to decide how to allocate a budget of 300 million shekels (approximately US$85 million) across 430 candidate technologies – mostly pharmaceuticals, and with a combined total cost of more than a billion shekels – resulting in 61 being added to the health basket [2]

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.